Market Place
Sourcing Support
SciSparc Secures FDA Approval For Ph 2b Tourette Treatment Trial
30 Sep 2024 //
GLOBENEWSWIRE
SciSparc Signs LOI To Sell Stake In MitoCareX
26 Sep 2024 //
GLOBENEWSWIRE
SciSparc FDA Approval For Phase IIb Tourette Syndrome Trial
23 Sep 2024 //
GLOBENEWSWIRE
SciSparc Submits IND For Tourette Syndrome Trial
18 Sep 2024 //
GLOBENEWSWIRE
SciSparc-Clearmind Patent For Ibogaine Combination Therapy
16 Sep 2024 //
GLOBENEWSWIRE
SciSparc Advances $1.85M Loan To AutoMax For Chinese Vehicle Import Deal
11 Sep 2024 //
GLOBENEWSWIRE
Clearmind Publishes Patent For MDMA-Based Combination Treatment
06 Sep 2024 //
GLOBENEWSWIRE
SciSparc-Clearmind Ketamine-Based Combination Patent Application Published
29 Aug 2024 //
GLOBENEWSWIRE
SciSparc Grants Global Rights For Pain Therapy In $6 Million Agreement
28 Aug 2024 //
GLOBENEWSWIRE
SciSparc Submits IND Application To FDA For SCI-110 Phase IIb Trial
24 Aug 2024 //
GLOBENEWSWIRE
SciSparc: MitoCareX Appoints Professor Nir Peled To Advisory Board
22 Aug 2024 //
GLOBENEWSWIRE
SciSparc Enrolls First Five Patients In SCI-210 Treatment Clinical Trial
19 Aug 2024 //
GLOBENEWSWIRE
Polyrizon Licenses SciSparc`s Preclinical Cannabinoid Pain Therapy
19 Aug 2024 //
FIERCE BIOTECH
SciSparc Finalizes Global Out-Licensing Deal For Pain Therapy Valued At $3M
16 Aug 2024 //
GLOBENEWSWIRE
SciSparc Updates Regarding the Status of the AutoMax Merger
14 Aug 2024 //
GLOBENEWSWIRE
SciSparc-Clearmind Collaboration Yields Weight Loss Drug Potential
06 Aug 2024 //
GLOBENEWSWIRE
MitoCareX Confirms Drug Target`s Role In Non-Small Cell Lung Cancer
22 Jul 2024 //
GLOBENEWSWIRE
SciSparc Signs LOI For $6M Pain Treatment Out-Licensing Deal
17 Jul 2024 //
GLOBENEWSWIRE
SciSparc Files US Patent For Metabolic Syndrome And Weight Loss
16 Jul 2024 //
GLOBENEWSWIRE
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
16 Jul 2024 //
GLOBENEWSWIRE
SciSparc Signs LOI To Spin Off Pharmaceutical Portfolio
08 Jul 2024 //
GLOBENEWSWIRE
SciSparc Secures Strategic Advantage with Grant of European Patent
31 May 2024 //
GLOBENEWSWIRE
SciSparc to Acquire AutoMax
11 Apr 2024 //
GLOBENEWSWIRE
SciSparc- Clearmind Collab Evolves with New International Patent Application
27 Mar 2024 //
GLOBENEWSWIRE
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure
21 Mar 2024 //
GLOBENEWSWIRE
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
18 Mar 2024 //
GLOBENEWSWIRE
SciSparc Achieves Milestone with Patient Dosed in Autism Spectrum Disorder Trial
14 Mar 2024 //
GLOBENEWSWIRE
SciSparc: MitoCareX Reveals Promising Results
12 Mar 2024 //
GLOBENEWSWIRE
SciSparc Announces Enrollment of First Patient for Clinical Trial for Children
08 Mar 2024 //
GLOBENEWSWIRE
SciSparc Issued Patent for Opioids Reduction Use in Pain Management Technology
06 Mar 2024 //
GLOBENEWSWIRE
SciSparc-Clearmind Partnership Yields Three International Patent Applications
27 Feb 2024 //
GLOBENEWSWIRE
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio
20 Feb 2024 //
GLOBENEWSWIRE
SciSparc Announces Initiation of Patient Recruitment for trial with SCI-210
29 Jan 2024 //
BIOSPACE
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
24 Jan 2024 //
GLOBENEWSWIRE
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company
19 Jan 2024 //
GLOBENEWSWIRE
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023
04 Jan 2024 //
GLOBENEWSWIRE
SciSparc Announces Positive Results for MitoCareX with Drug Discovery Platform
13 Dec 2023 //
GLOBENEWSWIRE
SciSparc Provides Updates Regarding Letter of Intent to Acquire Company
07 Dec 2023 //
GLOBENEWSWIRE
SciSparc`s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
01 Dec 2023 //
BIOSPACE
SciSparc Announces Results from Weight Loss and Metabolic Disorder Program
28 Nov 2023 //
GLOBENEWSWIRE
SciSparc Adopts Limited Duration Shareholder Rights Plan
28 Nov 2023 //
GLOBENEWSWIRE
SciSparc Announces Results for MitoCareX Bio with its Drug Discovery Platform
27 Nov 2023 //
GLOBENEWSWIRE
SciSparc`s patented CBD- Enhanced Solution for Autism Spectrum Disorder
24 Nov 2023 //
GLOBENEWSWIRE
SciSparc Signs Non-Binding Letter of Intent to Merge with Vehicle Importer
22 Nov 2023 //
GLOBENEWSWIRE
SciSparc Celebrates Major Breakthrough
15 Nov 2023 //
GLOBENEWSWIRE
SciSparc Aims to Change Tourette Syndrome Treatments
10 Nov 2023 //
GLOBENEWSWIRE
SciSparc Granted Patent for Reduction of Opioids Use
31 Oct 2023 //
GLOBENEWSWIRE
SciSparc Granted Patent for Core Technology From the Australian Patent Office
24 Oct 2023 //
GLOBENEWSWIRE
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
16 Oct 2023 //
GLOBENEWSWIRE
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
13 Oct 2023 //
GLOBENEWSWIRE
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
11 Oct 2023 //
GLOBENEWSWIRE
SciSparc Granted European Patent for its Core Technology
03 Oct 2023 //
GLOBENEWSWIRE
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics
29 Sep 2023 //
GLOBENEWSWIRE
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
27 Sep 2023 //
GLOBENEWSWIRE
SciSparc Announces 1-for-26 Reverse Share Split
20 Sep 2023 //
GLOBENEWSWIRE
SciSparc Engages Investment Bank to Identify Transaction Opportunities
12 Sep 2023 //
GLOBENEWSWIRE
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance
07 Sep 2023 //
GLOBENEWSWIRE
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of SCI-110
07 Sep 2023 //
GLOBENEWSWIRE
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
14 Aug 2023 //
GLOBENEWSWIRE
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
10 Aug 2023 //
GLOBENEWSWIRE
